...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distribution

Some of the funds may be funnelled to RVX. We'll know better in the next financials and MD&A.

But I'm sure ZCC still generates some expense even though BP bears the biggest cost of the many ongoing clinical trials.

But the biggest question to me is, who is selling ZHCLF shares for just pennies when the horizon for ZCC looks very favourable?

 

Koo

Share
New Message
Please login to post a reply